Prime Medicine, Inc. (NASDAQ: PRME) reported Q3 EPS of ($0.32), $0.11 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $1 million, versus $0 reported last year.

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.